Occlutech

Occlutech is a specialist medical device company focused on minimally invasive cardiac implants. Founded in 2003, the company has developed, manufactured and commercialized cardiac devices for three main therapeutic areas: Congenital Heart Disease, Stroke Prevention & Adult Intervention, and Heart Failure. Its products are sold to hospitals and clinics in more than 70 countries, and the company states that over 220,000 of its occluders have been implanted worldwide. The company describes itself as a leading specialist provider of minimally invasive cardiac devices, with a mission to improve the quality of life for people with heart conditions. Occlutech's origins lie in a request from Prof. Hans Figulla at Jena University Hospital in Germany, who in 2003 asked the company's engineers to develop a new generation of occluders aimed at reducing the amount of implanted material while increasing flexibility and adaptability when closing septum defects. The resulting Occlutech Figulla ranges of PFO and ASD occluders were launched in early 2007, using braiding technology and clamp-free shaping. Since then, the company has expanded its portfolio to include devices for heart failure, such as the Occlutech Atrial Flow Regulator (AFR), a Nitinol implant designed to maintain an interatrial shunt created by Balloon Atrial Septostomy. Occlutech is registered in Switzerland and employs around 300 people. It has manufacturing and R&D facilities in Germany and Türkiye, a global finance and distribution hub in Helsingborg, Sweden, and clinical operations in Minneapolis, United States. The company reports a history of more than 20 years, over 200 patents, more than 10 product lines across three therapeutic areas, and cumulative sales of more than 225,000 devices between 2007 and 2025. Its products are used by thousands of physicians each year, and the company emphasizes quality and consistent performance as key to that trust. The company's portfolio is built on proprietary Nitinol-based technology. Its flagship offerings include the Figulla range of septal occluders for PFO and ASD closure, and the Atrial Flow Regulator for heart failure. Occlutech positions itself as an innovation-driven specialist, collaborating with healthcare professionals to design and commercialize best-in-class cardiac devices. Its tagline, "Every beat counts," reflects its focus on cardiac care.

Occlutech's history is closely tied to the development of minimally invasive septal occluders. In the mid-1970s, Dr. Terry D. King and Dr. Noel I. Mills applied for a patent for an invention that allowed physicians to treat septum defects such as ASD or PFO without open-heart surgery for the first time. Their design combined features that remain state-of-the-art in modern occlusion devices: low profile, foldability, and a minimally invasive approach. Dr. King is known as the first physician to perform such a procedure. Their invention inspired technicians and physicians to improve the therapy field, leading to a number of new technologies and devices in the following decades. One of the most successful was the Amplatzer range of occluders, manufactured from a braided tube and clamped at the opposite ends. In 2003, Occlutech's engineers were asked by Prof. Hans Figulla at Jena University Hospital, Germany, to develop a new generation of occluders with the aim of reducing the amount of implanted material and increasing flexibility and adaptability when closing septum defects. The result was the Occlutech Figulla ranges of PFO and ASD occluders, launched in early 2007. Through groundbreaking braiding technology and clamp-free shaping, this represented another milestone in the development of septal occluders. Since its founding in 2003, Occlutech has developed, produced and commercialized minimally invasive cardiac implants for Congenital Heart Disease, Stroke Prevention, and Heart Failure. The company has expanded its portfolio beyond septal occluders to include the Occlutech Atrial Flow Regulator (AFR), a Nitinol implant designed to address unmet medical needs of heart failure patients despite optimal medical therapy. The AFR is implanted on the interatrial septum using routine, minimally invasive procedures and is intended to permanently maintain the interatrial communication created by Balloon Atrial Septostomy (BAS), allowing controlled blood flow from the left to the right atrium. Occlutech is registered in Switzerland and employs around 300 people. It has manufacturing and R&D facilities in Germany and Türkiye, a global finance and distribution hub in Helsingborg, Sweden, and clinical operations in Minneapolis, U.S. The company reports a history of more than 20 years, over 200 patents, more than 10 product lines across three therapeutic areas, and cumulative sales of more than 225,000 devices between 2007 and 2025. Its devices are sold to hospitals and clinics in over 70 countries and used by physicians in implantation procedures. The company states that over 220,000 occluders have been implanted in over 70 countries, and that its products are implanted in thousands of human hearts every year.

• 2025

  Cumulative sales of more than 225,000 devices reported for the period 2007–2025.

• 2007

  Occlutech Figulla ranges of PFO and ASD occluders launched in early 2007.

• 2003

  Occlutech founded; engineers asked by Prof. Hans Figulla to develop a new generation of occluders.

Leading specialist provider of minimally invasive cardiac devices, focused on innovation and best-in-class cardiac implants.

• Occlutech Figulla PFO occluder

  A septal occluder for patent foramen ovale closure, launched in early 2007.

• Occlutech Figulla ASD occluder

  A septal occluder for atrial septal defect closure, launched in early 2007.

• Occlutech Atrial Flow Regulator (AFR)

  A Nitinol cardiac implant designed to maintain an interatrial shunt created by Balloon Atrial Septostomy for heart failure patients.

1. 1Occlutech - Every beat countsocclutech.com
2. 2History - Occlutech - Every beat countsocclutech.com
3. 3Occlutech AFR (ATRIAL FLOW REGULATOR) - Occlutech - Every beat countsocclutech.com
4. 4About us - Occlutech - Every beat countsocclutech.com
5. 5Occlutech (Sweden) - Wikidatawikidata.org